Latest Shareholder Options News

Santos Limited has agreed to extend the exclusivity period with the XRG Consortium, allowing more time to finalize due diligence for a potential A$8.89 per share cash takeover. The extension keeps the door open for competing bids, maintaining shareholder options.

American West Metals has launched an offer of over 104 million new options to select investors and advisors, potentially raising $6.28 million upon exercise. The move aims to enhance liquidity and support ongoing exploration projects.

Lodestar Minerals has launched a revised loyalty options offer, increasing the allocation ratio to one option per twenty shares, aiming to reward shareholders and potentially raise capital.

FinTech Chain Limited has requested suspension of its shares from ASX trading to enable its removal from the official list, marking a significant shift for the fintech company.

Black Rock Mining Limited has launched a prospectus offering over 108 million unquoted options to participants of a recent $5 million placement, aiming to support the development of its Mahenge Graphite Project in Tanzania.

Pact Group Holdings Ltd has requested suspension of its shares from ASX trading as it prepares for removal from the official list, signaling a major shift for investors.

Kinterra Capital has applied to the Takeovers Panel to halt New World Resources’ $10 million placement, arguing it could block rival bids amid an ongoing takeover dispute.

Cauldron Energy Limited has announced a fully underwritten entitlement offer to raise nearly $2 million, aimed at advancing its Yanrey Uranium Project and shoring up working capital. The offer, priced at $0.006 per share, could reshape shareholder control dynamics depending on participation.

Fintech Chain Limited has applied to delist from the ASX, citing low valuation, poor liquidity, and high costs, aiming to unlock growth capital in China and the US.

Infinity Mining Limited has successfully closed a pro-rata entitlement issue, raising over $280,000 through new options set to be listed on the ASX next week.

Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.

Ansell Limited has updated its FY25 interim dividend details, confirming a payment of USD 0.222 per share with an AUD equivalent of 0.3486, payable on March 6, 2025.